|
**Overview**: Weil-Felix Test Panel**Introduction**: The Weil-Felix Test Panel is a diagnostic tool designed for rickettsial infection screening using serum samples. In India, rickettsial diseases (scrub typhus, Indian tick typhus, murine typhus) cause ~10-20 percent of acute undifferentiated fevers in rural/tribal areas, with high mortality (~10-30 percent untreated) due to multi-organ failure. High morbidity from under-testing in rural/low-SES patients with fever, eschar, rash, or headache, limited serology labs, delayed doxycycline leading to complications or misdiagnosis as dengue/typhoid. Per microbiology practices aligned with ICMR, National Centre for Disease Control, and IDSP guidelines, the test employs immunoassay for OX-2, OX-19, and OX-K antigens over 1â€"2 days with high accuracy, valuable for presumptive diagnosis in endemic areas (titre rise or >1:160 significant). This diagnostic falls under infectious disease screening and targets patients with fever + eschar/rash in monsoon/rural settings, addressing accurate detection to guide doxycycline therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling rapid rickettsial profiling and reducing mortality in high-burden regions. Its serum-based approach ensures reliable antibody detection.**Other Names**: Weil Felix Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/immunology, compliant with 2025 standards.**Historical Milestone**: Weil-Felix test standard in rickettsial endemic areas; in India, widely used despite newer assays.**Purpose**: The test assesses 3 parameters including OX-2 to guide rickettsial infection screening, detect antibodies, inform doxycycline therapy.**Test Parameters**: 1. OX-2, 2. OX-19, 3. OX-K.**Pretest Condition**: No fasting required; patients should have fever + rash/eschar.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on fever duration, eschar, tick exposure.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated rickettsia including death, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Rising titre or high OX-K/OX-19 indicates rickettsial infection, necessitating specialist input.**Specialist Consultation**: Infectious disease specialists should be consulted for management.**Additional Supporting Tests**: IgM ELISA, PCR for confirmation.**Test Limitations**: Cross-reactivity possible; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, Rickettsial Studies India 2023. |
